Independence Bank of Kentucky Has $1.98 Million Holdings in Pfizer Inc. (NYSE:PFE)

Independence Bank of Kentucky trimmed its position in shares of Pfizer Inc. (NYSE:PFEFree Report) by 8.0% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 68,678 shares of the biopharmaceutical company’s stock after selling 5,940 shares during the period. Independence Bank of Kentucky’s holdings in Pfizer were worth $1,977,000 as of its most recent SEC filing.

A number of other large investors also recently modified their holdings of the company. Front Street Capital Management Inc. boosted its stake in shares of Pfizer by 4.3% in the first quarter. Front Street Capital Management Inc. now owns 5,168 shares of the biopharmaceutical company’s stock worth $268,000 after acquiring an additional 215 shares during the period. Graves Light Lenhart Wealth Inc. boosted its stake in shares of Pfizer by 1.4% in the second quarter. Graves Light Lenhart Wealth Inc. now owns 19,863 shares of the biopharmaceutical company’s stock worth $729,000 after acquiring an additional 281 shares during the period. Infrastructure Capital Advisors LLC boosted its stake in shares of Pfizer by 5.2% in the second quarter. Infrastructure Capital Advisors LLC now owns 5,751 shares of the biopharmaceutical company’s stock worth $211,000 after acquiring an additional 284 shares during the period. Castleview Partners LLC boosted its stake in shares of Pfizer by 2.4% in the first quarter. Castleview Partners LLC now owns 12,207 shares of the biopharmaceutical company’s stock worth $498,000 after acquiring an additional 287 shares during the period. Finally, United Bank boosted its stake in shares of Pfizer by 0.6% in the first quarter. United Bank now owns 46,671 shares of the biopharmaceutical company’s stock worth $2,416,000 after acquiring an additional 290 shares during the period. 68.36% of the stock is owned by hedge funds and other institutional investors.

Pfizer Price Performance

NYSE:PFE opened at $27.23 on Thursday. The company has a debt-to-equity ratio of 0.69, a current ratio of 0.91 and a quick ratio of 0.69. The business has a 50 day simple moving average of $27.41 and a 200-day simple moving average of $29.25. Pfizer Inc. has a 1 year low of $25.61 and a 1 year high of $42.22. The firm has a market capitalization of $154.19 billion, a price-to-earnings ratio of 75.64, a PEG ratio of 1.23 and a beta of 0.61.

Pfizer (NYSE:PFEGet Free Report) last issued its quarterly earnings results on Tuesday, January 30th. The biopharmaceutical company reported $0.10 earnings per share for the quarter, topping the consensus estimate of ($0.19) by $0.29. Pfizer had a return on equity of 10.88% and a net margin of 3.62%. The firm had revenue of $14.25 billion for the quarter, compared to the consensus estimate of $14.37 billion. During the same period in the prior year, the business posted $1.14 earnings per share. The company’s revenue for the quarter was down 41.3% on a year-over-year basis. Equities analysts forecast that Pfizer Inc. will post 2.22 EPS for the current year.

Analysts Set New Price Targets

A number of equities analysts have recently weighed in on PFE shares. TD Cowen lowered Pfizer from an “outperform” rating to a “market perform” rating and set a $32.00 price objective for the company. in a research note on Thursday, January 4th. Barclays dropped their price target on Pfizer from $34.00 to $28.00 and set an “equal weight” rating for the company in a research note on Thursday, December 14th. UBS Group dropped their price target on Pfizer from $34.00 to $27.00 and set a “neutral” rating for the company in a research note on Thursday, December 14th. Guggenheim began coverage on Pfizer in a research note on Friday, February 23rd. They set a “buy” rating and a $36.00 price target for the company. Finally, Cantor Fitzgerald reissued an “overweight” rating and set a $45.00 price target on shares of Pfizer in a research note on Monday. Twelve analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. Based on data from MarketBeat.com, Pfizer presently has a consensus rating of “Hold” and a consensus target price of $36.88.

View Our Latest Stock Report on PFE

Pfizer Profile

(Free Report)

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.

Read More

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.